Related Experiment Video
Updated: May 19, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Molecular-targeted therapies for ovarian cancer: prospects for the future
1Section of Translational Research and Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kita-Oji, Akashi, Hyogo 673-8558, Japan. reikeih@wine.ocn.ne.jp
Abstract:
Ovarian cancer accounts for approximately 4 % of cancer deaths in women worldwide, with around 225,000 estimated new cases diagnosed each year and 140,000 related deaths. Prompt diagnosis is challenging because of the non-specific symptoms exhibited during the early stages of the disease; consequently, 50 % of cases present with advanced metastatic cancer, and 5-year survival rates are limited to 10-30 %. Furthermore, disease recurrence occurs in a high proportion of cases, and the survival rate is only 30 % even in patients who are sensitive to platinum-based chemotherapy. This review describes the increased characterization of the molecular mechanisms involved in the development and progression of ovarian cancer, and how this has resulted in improved therapeutic strategies with molecular-targeted agents. These include targeting BRCA mutations to affect DNA repair, inhibition of the mTOR and MAPK pathways, and anti-angiogenesis therapies. Ultimately, personalized therapy using novel biomarkers in parallel with improved early detection techniques could significantly enhance the prognosis of ovarian cancer patients.
Insights
This review highlights advances in understanding ovarian cancer
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ovarian cancer is a leading cause of cancer death in women, often diagnosed at advanced stages.
- Non-specific early symptoms and high recurrence rates limit survival.
- Current survival rates for advanced or recurrent disease remain poor.
Purpose of the Study:
- To review the molecular mechanisms driving ovarian cancer development and progression.
- To discuss how this knowledge has informed the development of targeted therapies.
- To explore future directions for improving patient prognosis.
Main Methods:
- Literature review of molecular mechanisms in ovarian cancer.
- Analysis of current and emerging targeted therapeutic strategies.
- Discussion of novel biomarkers and early detection methods.
Main Results:
- Detailed characterization of molecular pathways involved in ovarian cancer.
- Identification of targeted agents including BRCA mutation targeting, mTOR/MAPK pathway inhibition, and anti-angiogenesis therapies.
- Emphasis on the potential of personalized medicine.
Conclusions:
- Advances in molecular understanding have led to improved targeted therapies for ovarian cancer.
- Personalized therapy combined with early detection offers significant potential to enhance patient outcomes.
- Further research into biomarkers and detection is crucial for improving ovarian cancer prognosis.
More Related Videos
09:40Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
07:54Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
Published on: March 25, 2019
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...